studies

mML - 1st line (L1), ... vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMspire-170, 2020 (REV) 0.94 [0.62; 1.44] 0.94[0.62; 1.44]IMspire-170, 2020 (REV)10%446NAnot evaluable progression or deaths (PFS)detailed resultsIMspire-170, 2020 (REV) 0.87 [0.67; 1.14] 0.87[0.67; 1.14]IMspire-170, 2020 (REV)10%446NAnot evaluable DCRdetailed resultsIMspire-170, 2020 (REV) 1.09 [0.75; 1.59] 1.09[0.75; 1.59]IMspire-170, 2020 (REV)10%446NAnot evaluable objective responses (ORR)detailed resultsIMspire-170, 2020 (REV) 1.30 [0.85; 1.99] 1.30[0.85; 1.99]IMspire-170, 2020 (REV)10%446NAnot evaluable AE (any grade)detailed resultsIMspire-170, 2020 (REV) 0.07 [0.02; 0.30] 0.07[0.02; 0.30]IMspire-170, 2020 (REV)10%436NAnot evaluable AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.25 [0.17; 0.37] 0.25[0.17; 0.37]IMspire-170, 2020 (REV)10%436NAnot evaluable AE leading to death (grade 5)detailed resultsIMspire-170, 2020 (REV) 0.72 [0.23; 2.31] 0.72[0.23; 2.31]IMspire-170, 2020 (REV)10%436NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 1.02 [0.14; 7.30] 1.02[0.14; 7.30]IMspire-170, 2020 (REV)10%436NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.57 [0.17; 1.99] 0.57[0.17; 1.99]IMspire-170, 2020 (REV)10%436NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 1.02 [0.02; 51.57] 1.02[0.02; 51.57]IMspire-170, 2020 (REV)10%436NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.57 [0.17; 1.99] 0.57[0.17; 1.99]IMspire-170, 2020 (REV)10%436NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 1.02 [0.02; 51.57] 1.02[0.02; 51.57]IMspire-170, 2020 (REV)10%436NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.51 [0.02; 15.23] 0.51[0.02; 15.23]IMspire-170, 2020 (REV)10%436NAnot evaluable Dermatitis acneiform AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.04 [0.00; 0.75] 0.04[0.00; 0.75]IMspire-170, 2020 (REV)10%436NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.23 [0.07; 0.68] 0.23[0.07; 0.68]IMspire-170, 2020 (REV)10%436NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.61 [0.14; 2.57] 0.61[0.14; 2.57]IMspire-170, 2020 (REV)10%436NAnot evaluable Headache AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.51 [0.02; 15.23] 0.51[0.02; 15.23]IMspire-170, 2020 (REV)10%436NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.57 [0.23; 1.38] 0.57[0.23; 1.38]IMspire-170, 2020 (REV)10%436NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.33 [0.07; 1.67] 0.33[0.07; 1.67]IMspire-170, 2020 (REV)10%436NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.50 [0.12; 2.03] 0.50[0.12; 2.03]IMspire-170, 2020 (REV)10%436NAnot evaluable Increased Lipase Level AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.50 [0.15; 1.69] 0.50[0.15; 1.69]IMspire-170, 2020 (REV)10%436NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.10 [0.01; 1.84] 0.10[0.01; 1.84]IMspire-170, 2020 (REV)10%436NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 1.02 [0.06; 16.39] 1.02[0.06; 16.39]IMspire-170, 2020 (REV)10%436NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 1.02 [0.02; 51.57] 1.02[0.02; 51.57]IMspire-170, 2020 (REV)10%436NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.17 [0.02; 1.39] 0.17[0.02; 1.39]IMspire-170, 2020 (REV)10%436NAnot evaluable Rash AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.13 [0.03; 0.57] 0.13[0.03; 0.57]IMspire-170, 2020 (REV)10%436NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.13 [0.01; 2.38] 0.13[0.01; 2.38]IMspire-170, 2020 (REV)10%436NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.08 [0.00; 1.49] 0.08[0.00; 1.49]IMspire-170, 2020 (REV)10%436NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMspire-170, 2020 (REV) 0.40 [0.08; 2.09] 0.40[0.08; 2.09]IMspire-170, 2020 (REV)10%436NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-07-07 00:41 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 285,68,127,128 - treatments: 359

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons